Innoviva (INVA) Upgraded to Hold by BidaskClub
BidaskClub upgraded shares of Innoviva (NASDAQ:INVA) from a sell rating to a hold rating in a research note issued to investors on Thursday.
Several other research analysts also recently commented on the stock. ValuEngine downgraded shares of Innoviva from a hold rating to a sell rating in a research note on Tuesday. Zacks Investment Research raised shares of Innoviva from a strong sell rating to a hold rating in a research note on Tuesday, June 26th. Finally, Stifel Nicolaus reissued a hold rating and set a $16.00 price target on shares of Innoviva in a research note on Monday, June 25th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. The company has an average rating of Hold and an average target price of $13.67.
Innoviva stock traded down $0.08 during mid-day trading on Thursday, hitting $14.51. 7,185 shares of the company traded hands, compared to its average volume of 562,911. Innoviva has a one year low of $11.47 and a one year high of $17.99. The firm has a market cap of $1.50 billion, a PE ratio of 12.54 and a beta of 2.26. The company has a debt-to-equity ratio of -3.13, a current ratio of 26.39 and a quick ratio of 26.39.
In other Innoviva news, VP Theodore J. Jr. Witek sold 8,504 shares of Innoviva stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $14.12, for a total transaction of $120,076.48. Following the transaction, the vice president now directly owns 256,271 shares of the company’s stock, valued at $3,618,546.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of INVA. SG Americas Securities LLC purchased a new position in shares of Innoviva in the first quarter worth $113,000. OppenheimerFunds Inc. purchased a new position in shares of Innoviva in the second quarter worth $142,000. Jane Street Group LLC purchased a new position in shares of Innoviva in the second quarter worth $147,000. Itau Unibanco Holding S.A. purchased a new position in shares of Innoviva in the second quarter worth $167,000. Finally, Stevens Capital Management LP purchased a new position in shares of Innoviva in the second quarter worth $183,000. 72.69% of the stock is currently owned by institutional investors.
Innoviva Company Profile
Innoviva, Inc engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI).
Featured Article: What Factors Can Affect Return on Equity?
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.